Additional file 1: of Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

Comparison between the baseline characteristics of patients monitored (V1 V2) and those who had no data on V2 (noV1 V2). (DOCX 15 kb)